93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…
December 05, 2025 20:00 ET | Source: ORIC Pharmaceuticals Highly differentiated 1L preliminary systemic activity of 67% ORR and 100%…
December 05, 2025 01:00 ET | Source: ORIC Pharmaceuticals Systemic activity of 35% ORR in 2L+ patients, including in patients…
November 18, 2025 16:30 ET | Source: Protara Therapeutics NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…
November 08, 2025 17:13 ET | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…
In Partnership with the International League of Dermatological Societies (ILDS) and the International Society of Dermatology (ISD), CeraVe Mobilizes 9…
MINNEAPOLIS and BRISBANE, Australia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR,…
MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company)…